Acute intermittent porphyria (AIP) is a rare, genetically dominant metabolic disorder characterized by abnormalities in the production of heme, the central component of hemoglobin. AIP is caused due to a deficiency of porphobilinogen deaminase (PBGD) enzyme which is involved in the heme biosynthesis pathway. Symptoms of AIP include severe abdominal pain, nausea, and vomiting caused due to abnormal accumulation of porphyrin precursors in the nervous system and other tissues. Treatment mainly involves intravenous hemo therapy to reduce levels of delta-aminolevulinic acid and prevent crisis. Additionally, anticonvulsants and opioid analgesics are used to alleviate pain associated with the condition.
The acute intermittent porphyria market is estimated to be valued at USD 1.43 Billion in 2024 and is expected to reach USD 2.17 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031.
Key Takeaways
Key players operating in the acute intermittent porphyria market are Alnylam Pharmaceuticals, Recordati Rare Diseases Inc., and Retrophin.
Growing research and developments for effective therapeutics and rising awareness regarding hereditary porphyrias present significant growth opportunities in Acute Intermittent Porphyria Market.
Favorable regulatory environment and reimbursement schemes as well as collaborations with local healthcare providers are fueling the expansion of global acute intermittent porphyria market in regions such as Asia Pacific and Latin America.
Market drivers
Increasing disease prevalence worldwide owing to rising environmental toxins and genetic predisposition is a major factor augmenting the market growth. It is estimated that around 1-2 new cases of AIP are diagnosed per million population each year. Other critical factors such as improved diagnosis, government initiatives for rare disease treatment, and strong product pipeline are also propelling the acute intermittent porphyria market.
PEST Analysis
Political: Government regulations regarding the testing and marketing approval process for drugs can impact the acute intermittent porphyria market. Regulations aim to ensure drug safety and efficacy.
Economic: Growth in the economy and disposable income levels affect healthcare spending and thus demand for drugs in the acute intermittent porphyria market. Recessions may decrease discretionary spending on healthcare.
Social: Increased awareness about acute intermittent porphyria and its treatment options via social media and patient communities can drive people to seek diagnosis and treatment. Changing lifestyles also affect disease prevalence over time.
Technological: Advancements in genetic testing technologies help facilitate accurate and early diagnosis of acute intermittent porphyria. Development of new drug delivery methods, formulations and devices can expand treatment options in the market.
Geographical Regions of Concentration
The market for acute intermittent porphyria is primarily concentrated in North America and Europe in terms of value. This is because these regions have higher healthcare spends per capita and greater awareness levels regarding this rare disease. Many global key players are also based in America and Europe, ensuring easy access to treatment drugs.
Fastest Growing Region
Asia Pacific region is expected to grow the fastest in the acute intermittent porphyria drug market during the forecast period. This is attributed to factors like rising incidence of porphyrias due to increasing environmental toxins, rapidly developing healthcare infrastructure and growing medical tourism in the region. Moreover, presence of generic drugs manufacturers will support market growth at a lower cost of treatment.
Get This Report in Japanese Language: 急性間欠性ポルフィリン症市場
Get This Report in Korean Language: 급성 간헐성 포르피린증 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)
